president trump
The media, including the Drudge Report, is mocking President Trump for his comments at Thursday's White House coronavirus task force briefing where he tossed out suggestions for treating patients along the lines of chemo-therapy or light therapy.

Here is what President Trump said. Excerpt from White House transcript:

THE PRESIDENT: Thank you very much. So I asked Bill a question that probably some of you are thinking of, if you're totally into that world, which I find to be very interesting. So, supposing we hit the body with a tremendous — whether it's ultraviolet or just very powerful light — and I think you said that that hasn't been checked, but you're going to test it. And then I said, supposing you brought the light inside the body, which you can do either through the skin or in some other way, and I think you said you're going to test that too. It sounds interesting.

ACTING UNDER SECRETARY BRYAN: We'll get to the right folks who could.

THE PRESIDENT: Right. And then I see the disinfectant, where it knocks it out in a minute. One minute. And is there a way we can do something like that, by injection inside or almost a cleaning. Because you see it gets in the lungs and it does a tremendous number on the lungs. So it would be interesting to check that. So, that, you're going to have to use medical doctors with. But it sounds — it sounds interesting to me.

So we'll see. But the whole concept of the light, the way it kills it in one minute, that's — that's pretty powerful...

THE PRESIDENT: ...I have to say, it covers a lot more territory than just this. This is — this is probably an easy thing, relatively speaking, for you.

I would like you to speak to the medical doctors to see if there's any way that you can apply light and heat to cure. You know — but if you could. And maybe you can, maybe you can't. Again, I say, maybe you can, maybe you can't. I'm not a doctor. But I'm like a person that has a good you know what.

Q But, sir, you're the President.

THE PRESIDENT: Deborah, have you ever heard of that? The heat and the light, relative to certain viruses, yes, but relative to this virus?

DR. BIRX: Not as a treatment. I mean, certainly fever —

THE PRESIDENT: Yeah.

DR. BIRX: — is a good thing. When you have a fever, it helps your body respond. But not as — I've not seen heat or (inaudible).

THE PRESIDENT: I think it's a great thing to look at. I mean, you know. Okay?

Apparently Dr. Birx has not heard about this pioneering light treatment being studied announced a few days ago.

Earlier this week, the bio-tech firm Aytu BioScience announced they are partnering with the FDA and Cedars-Sinai on a UV light treatment to kill the coronavirus in intubated patients.

Video illustrating treatment:

The company released a press release, which is posted here in full (less corporate and disclaimer info at the end):
Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment

Cedars-Sinai-Developed 'Healight' Medical Device Platform Technology Being Studied as a Potential First-in-Class COVID-19 Treatment

Conference Call Scheduled for Tuesday, April 21, 2020 at 4:30 pm ET

ENGLEWOOD, CO / ACCESSWIRE / April 20, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has signed an exclusive worldwide license from Cedars-Sinai to develop and commercialize the Healight Platform Technology ("Healight"). This medical device technology platform, discovered and developed by scientists at Cedars-Sinai, is being studied as a potential first-in-class treatment for coronavirus and other respiratory infections.

The company will host a live conference call and webcast Tuesday, April 21, 2020 at 4:30 p.m. ET. Conference call details are provided at the end of this press release.

Led by Mark Pimentel, MD, the research team of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai has been developing the patent-pending Healight platform since 2016 and has produced a growing body of scientific evidence demonstrating pre-clinical safety and effectiveness of the technology as an antiviral and antibacterial treatment. The Healight technology employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel endotracheal medical device. Pre-clinical findings indicate the technology's significant impact on eradicating a wide range of viruses and bacteria, inclusive of coronavirus. The data have been the basis of discussions with the FDA for a near-term path to enable human use for the potential treatment of coronavirus in intubated patients in the intensive care unit (ICU). Beyond the initial pursuit of a coronavirus ICU indication, additional data suggest broader clinical applications for the technology across a range of viral and bacterial pathogens. This includes bacteria implicated in ventilator associated pneumonia (VAP).

"Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells," stated Dr. Pimentel of Cedars-Sinai. Ali Rezaie, MD, one of the inventors of this technology states, "Our lab at Cedars-Sinai has extensively studied the effects of this unique technology on bacteria and viruses. Based on our findings we believe this therapeutic approach has the potential to significantly impact the high morbidity and mortality of coronavirus-infected patients and patients infected with other respiratory pathogens. We are looking forward to partnering with Aytu BioScience to move this technology forward for the benefit of patients all over the world."

The company believes the Healight platform technology has the potential to positively impact outcomes for critically ill patients infected with coronavirus and severe respiratory infections. The company licensed exclusive worldwide rights to the technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. Patents have been filed by Cedars-Sinai Department of Technology Transfer, and Aytu BioScience will manage all aspects of intellectual property prosecution and filing globally. Aytu BioScience expects to partner the product outside the U.S.

"We are honored to be partnering with Cedars-Sinai as we believe the Healight therapeutic platform has the potential to help many patients during this coronavirus pandemic and beyond," said Josh Disbrow, Chairman and CEO of Aytu BioScience.

The Company is engaging with the research team at Cedars-Sinai and the FDA to determine an expedited regulatory process to potentially enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.

Disbrow continued, "This first-in-class technology has the potential to be a game changer for clinicians treating patients infected with coronavirus and other respiratory conditions, and our team is working tirelessly alongside the Cedars-Sinai team to determine the safety and effectiveness of this device in humans."